| abstract |
The present disclosure is directed to a composition regimen, a titration kit, and methods of administration to facilitate the initiation of the treatment of at least one central nervous system condition or disorder by administering a plurality of dosage units of at least one bifeprunox compound, such as 7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl ]-2(3H)-benzoxazolone (INN bifeprunox), according to a titration schedule. |